print_label | resize_label

FOR YOUR APPROPRIATE ADULT PATIENTS WITH TYPE 2 DIABETES, IN ADDITION TO DIET AND EXERCISE

DEMONSTRATED A1C REDUCTIONS WITH ONGLYZA

CLINICAL TRIALS

ONGLYZA HEAD-TO-HEAD VS A SULFONYLUREA

5 mg vs up-titrated glipizide as add-on to metformin IR

ONGLYZA demonstrated A1C reductions comparable to glipizide with lower rates of hypoglycemia1,2

 

ONGLYZA IN RENALLY IMPAIRED PATIENTS

2.5 mg vs placebo

ONGLYZA demonstrated significant A1C reductions with similar rates of hypoglycemia, in renally impaired patients1,3

 

ONGLYZA AS ADD-ON THERAPY

To metformin IR

ONGLYZA led to significant reductions in A1C when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone1,4

 

INITIAL COMBINATION THERAPY WITH ONGLYZA

5 mg + metformin IR

ONGLYZA given in combination with metformin as initial therapy improved glycemic control in patients with type 2 diabetes compared with ONGLYZA or metformin as monotherapy1,5